ERBB2 and renal pelvis/ureter urothelial carcinoma: Consistent with retrospective studies, prospective genomic profiling of 44,183 tumors including 1032 bladder and 204 UTUC at our institution using MSK-IMPACT revealed that mutations in ERBB2 (oncogenic/likely oncogenic) were more common in urothelial cancer (UC) than in other common solid tumors (10.3% in bladder and 5.9 % in UTUC as compared to 3.2% in breast, 2.9% in endometrial, 2.6% in colorectal, and 2.4% in NSCLC) (Fig. 5a).